Francesco Passiglia - Concepedia

Author

Francesco Passiglia

University of Turin ORCID

Also Known As

F Passiglia, F. Passiglia, Francesc Passiglia, Francesco Passiglia, Giulio Metro, Passiglia, F.

360

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

University of Turin Ospedale San Luigi Gonzaga Istituti di Ricovero e Cura a Carattere Scientifico Università Campus Bio-Medico University of Palermo

About

Francesco Passiglia is an author at University of Turin specializing in medicine, cancer therapeutics, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	447
2	Pathology	4	4	203
3	Immunology	2	2	111
4	Health Sciences	1	1	12
5	Pharmacology	1	1	75

Francesco Passiglia

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis Francesco Passiglia, Giuseppe Bronte, Viviana Bazan, Oncotarget	2016	165
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, European Journal of Cancer First-line PembrolizumabMedicinePathologyImmune Checkpoint InhibitorPoor Performance Status	2020	145
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Journal for ImmunoTherapy of Cancer	2021	132
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Journal for ImmunoTherapy of Cancer	2020	95
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna, Cancer Immunology Immunotherapy Advanced NsclcOncologyFirst-line Pembrolizumab EffectivenessPd-l1 ExpressionImmune Checkpoint Inhibitor	2020	87
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations Francesco Passiglia, Federico Cappuzzo, Oscar Alabiso, British Journal of Cancer	2018	85
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna, Clinical Lung Cancer Pd-l1 ExpressionClinical EpidemiologyImmunologyImmune Checkpoint InhibitorClinical Outcomes	2020	82
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects Giuseppe Bronte, Christian Rolfo, Elisa Giovannetti, Critical Reviews in Oncology/Hematology OncologyMedicineBronchial NeoplasmClinical AspectsPharmacotherapy	2013	75
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients Francesco Passiglia, Antonio Galvano, Marta Castiglia, Therapeutic Advances in Medical Oncology	2019	64
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion Mihaela Aldea, Arianna Marinello, M. Duruisseaux, Journal of Thoracic Oncology	2023	42

Page 1